Join the Lisdexamfetamine group to help and get support from people like you.
Lisdexamfetamine News
Community Health Workers Can Help Minority Kids Access ADHD Care
MONDAY, Aug. 25, 2025 — Community health workers could help extend care to more minority children with ADHD, a new pilot study says. Parents of kids with ADHD said they were more likely to consider m...
Current Medical Use of Rx Stimulants for ADHD Up in Teens From 2005 to 2023
TUESDAY, Aug. 5, 2025 – Among U.S. adolescents, current medical use of prescription stimulants for attention-deficit/hyperactivity disorder (ADHD) increased between 2005 and 2023, while nonmedical...
ADHD Medications Remain Linked to Lower Risk for Real-World Adverse Outcomes
WEDNESDAY, July 2, 2025 – Attention-deficit/hyperactivity disorder (ADHD) medications remain associated with a reduced risk for various real-world outcomes, but the magnitude of these associations...
FDA Medwatch Alert: FDA Requires Expanded Labeling About Weight Loss Risk in Patients Younger Than 6 Years Taking Extended-Release Stimulants for ADHD
FDA Drug Safety Communication - June 30, 2025 What safety concern is FDA announcing?The U.S. Food and Drug Administration (FDA) is revising the labeling of all extended-release stimulants indicated...
Many ADHD Medications Lead to Increases in Blood Pressure and Heart Rate
MONDAY, April 21, 2025 – Many pharmacological treatments for attention-deficit/hyperactivity disorder (ADHD) lead to increases in hemodynamic signs, including blood pressure and pulse, according to...
FDA Expands Uses of Vyvanse to Treat Binge-Eating Disorder
January 30, 2015 – The U.S. Food and Drug Administration today expanded the approved uses of Vyvanse (lisdexamfetamine dimesylate) to treat binge-eating disorder in adults. The drug is the first...
Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) Now Approved in the US for Maintenance Treatment in Adults with ADHD
PHILADELPHIA, February 7, 2012 /PRNewswire/ – Vyvanse (lisdexamfetamine dimesylate), an approved treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in patients ages 6 and above, is the...
FDA Approves Vyvanse (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
PHILADELPHIA - November 15, 2010 Shire plc, the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the prescription medication Vyvanse...
Further information
Related condition support groups
Binge Eating Disorder, Attention-Deficit Hyperactivity Disorder (ADHD), Chronic Fatigue Syndrome (CFS), Depression, Narcolepsy, Oppositional Defiant Disorder